![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 39/395 | |
A61K 31/506 | |||
A61K 31/44 | |||
A61P 35/00 | |||
A61K 45/06 | |||
A61K 31/404 | |||
A61K 31/675 | |||
A61K 31/436 | |||
A61K 31/665 |
(11) | Number of the document | 2593139 |
(13) | Kind of document | T |
(96) | European patent application number | 11807356.8 |
Date of filing the European patent application | 2011-07-11 | |
(97) | Date of publication of the European application | 2013-05-22 |
(45) | Date of publication and mention of the grant of the patent | 2017-08-23 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2011/043594 |
Date | 2011-07-11 |
(87) | Number | WO 2012/009288 |
Date | 2012-01-19 |
(30) | Number | Date | Country code |
201161470812 P | 2011-04-01 | US | |
201161470412 P | 2011-03-31 | US | |
363610 P | 2010-07-12 | US |
(72) |
HART, Charles, US
CURD, John, US
KROLL, Stewart, US
SUN, Jessica, US
|
(73) |
Threshold Pharmaceuticals, Inc.,
170 Harbor Way, Suite 300, South San Francisco, CA 94080,
US
|
(54) | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER |
ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER |